225220 — Genolution Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapNeutral

Annual income statement for Genolution, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	85,303	72,834	38,085	9,761	7,136
Cost of Revenue
Gross Profit	63,252	53,396	26,353	4,521	2,367
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	31,261	31,553	23,085	17,897	16,624
Operating Profit	54,041	41,281	14,999	-8,136	-9,488
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	43,281	43,533	17,239	-6,653	-6,771
Provision for Income Taxes
Net Income After Taxes	32,046	34,394	14,602	-5,550	-7,209
Minority Interest
Net Income Before Extraordinary Items
Net Income	32,046	34,394	14,602	-5,550	-6,826
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	32,046	34,394	14,602	-5,550	-6,826
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2,038	1,796	755	-174	-366
Dividends per Share